Welcome to our dedicated page for Imax SEC filings (Ticker: IMAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IMAX Corporation (NYSE: IMAX) files reports and disclosure documents with the U.S. Securities and Exchange Commission that provide detail on its entertainment technology business, capital structure, and material events. These SEC filings include current reports on Form 8-K, annual and quarterly reports, and other documents that describe the company’s convertible notes, credit facilities, and operating results.
Among its recent filings, IMAX has reported the entry into a Seventh Amended and Restated Credit Agreement, which increased its revolving borrowing capacity and set out leverage covenants, guarantees, and use of proceeds. The company has also filed an 8-K describing the issuance of 0.75% convertible senior notes due 2030, outlining interest terms, maturity, conversion rights, redemption conditions, and related capped call transactions intended to reduce potential dilution or offset certain cash payments upon conversion.
Investors reviewing IMAX filings can use this page to access documents that discuss the company’s financial obligations, including convertible debt, revolving credit facilities, and related covenants. Filings also reference IMAX’s global footprint, with systems operating in multiple countries and territories, and its listing on the New York Stock Exchange under the symbol IMAX.
Stock Titan’s SEC filings page for IMAX provides real-time access to new submissions from the EDGAR system, along with AI-powered summaries designed to explain the key terms and implications of complex filings. Users can quickly identify items related to financing transactions, results of operations, and other material corporate developments, and can locate information relevant to topics such as note conversion features, redemption provisions, and reporting covenants.
IMAX (IMAX) reported an insider transaction by CTO & EVP Pablo Calamera. On 11/10/2025, he executed a sale coded “S” of 20,586 common shares at a price of $34.2255 per share. Following the sale, his beneficially owned common shares total 40,886, held directly.
The filing also notes remaining restricted share units of 32,863 after the reported transactions. This Form 4 reflects a routine insider share sale and updated holdings.
IMAX filed a Form 144 indicating a proposed sale of 20,586 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $704,566.14 and an approximate sale date of 11/10/2025.
The shares to be sold were acquired via restricted stock vesting under a registered plan: 17,586 on 03/07/2024 and 3,000 on 03/07/2023, each for services rendered. Shares outstanding were 53,798,934; this is a baseline figure, not the amount being offered.
IMAX reported a Form 144 notice for a proposed sale of 49,504 common shares through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of $1,743,926.91 and an approximate sale date of 11/10/2025 on the NYSE. The shares were acquired on 11/10/2025 via the exercise of options under a registered plan, with payment in cash. As context, 53,798,934 shares were outstanding.
IMAX filed a Form 144 notice for a planned sale of 6,188 common shares. The filing lists Morgan Stanley Smith Barney as broker, an aggregate market value of $211,909.30, and an approximate sale date of 11/10/2025 on the NYSE.
The shares were acquired on 11/10/2025 through the exercise of options under a registered plan, with payment in cash. Shares outstanding were 53,798,934. The signer represents they do not know of undisclosed material adverse information about the company.
IMAX Corp (IMAX): Form 4 insider activity. On 11/07/2025, Chief Legal Officer and Sr. EVP Robert D. Lister exercised stock options to acquire 50,143 common shares at $22.49 pursuant to a Rule 10b5-1 plan dated June 11, 2025, then sold 50,143 shares at $34.6652 the same day. After these transactions, he directly beneficially owned 161,421 common shares. The filing notes remaining restricted share units of 70,609. The options were issued in 2019 and set to expire on March 7, 2026, and the derivative balance following these transactions is listed as 0.
IMAX — Form 144 notice of proposed sale: A holder filed to sell up to 50,143 shares of Class A Common on or about 11/07/2025 through Merrill Lynch on the NYSE, reflecting an aggregate market value of 1,738,215.
The shares to be sold were acquired on 11/07/2025 via an exercise of options under a registered plan, paid in cash. Over the prior three months, the person reported selling 20,000 shares on 09/15/2025 for gross proceeds of 656,029. Shares outstanding were 53,798,934.
IMAX Corporation completed a private Rule 144A sale of $250 million aggregate principal amount of 0.750% Convertible Senior Notes due 2030, including the full exercise of a $30 million option. The notes pay interest semi‑annually beginning May 15, 2026 and mature on November 15, 2030, unless earlier converted, redeemed, or repurchased.
Net proceeds are expected to be $241.1 million. IMAX plans to use the cash, along with cash on hand and borrowings under its credit facility, to fund capped call transactions and repurchase its 0.500% Convertible Senior Notes due 2026. The company agreed to repurchase $229.7 million principal of the 2026 notes for a total cash price of $276.0 million, including accrued interest.
The initial conversion rate is 23.5743 shares per $1,000 (conversion price ≈ $42.42) with customary adjustments; upon conversion, IMAX will settle in cash or cash plus shares. The capped call’s initial cap price is $57.1025 (a 75% premium to the November 3, 2025 close) and cost approximately $21.9 million. The notes are redeemable at IMAX’s option on or after November 20, 2028 if the share price exceeds 130% of the conversion price for the specified trading periods. An initial maximum of 7,661,650 shares may be issuable upon conversion based on the initial maximum conversion rate.
IMAX Corporation filed its Q3 2025 report, showing higher revenue and profit. Revenue for the quarter was $106.654 million, up from $91.452 million a year ago, as stronger image enhancement and maintenance services ($61.029 million) and technology rentals ($23.336 million) offset lower technology sales ($19.360 million). Gross margin rose to $67.271 million from $51.019 million, and income from operations increased to $29.045 million from $19.411 million.
Net income attributable to common shareholders was $20.657 million, or diluted EPS of $0.37, versus $13.896 million and $0.26 last year. Year‑to‑date operating cash flow reached $97.694 million, supporting cash and cash equivalents of $143.106 million as of September 30, 2025. Total assets were $889.573 million and total shareholders’ equity was $435.986 million. Debt consisted of $230.743 million in convertible notes and other borrowings and $26.477 million outstanding on the revolving credit facility. Deferred revenue increased to $64.505 million. Common shares outstanding were 53,798,934 as of September 30, 2025.
IMAX Corporation furnished a press release announcing its financial and operating results for the quarter ended September 30, 2025, under Item 2.02 of a Form 8-K.
The release is attached as Exhibit 99.1. The information is furnished, not filed, which means it is not subject to Section 18 of the Exchange Act and will be incorporated by reference only if specifically stated.
Robert D. Lister, Chief Legal Officer and Senior Executive Vice President of IMAX Corporation, reported a sale of common stock. On 09/15/2025 Mr. Lister sold 20,000 shares at a reported price of $32.80 per share under a 10b5-1 trading plan dated June 11, 2025. After the sale his reported beneficial ownership of common shares is 161,421. The filing also discloses his remaining equity holdings across compensation vehicles: 50,143 outstanding options and 70,609 restricted share units following the transaction. The Form 4 was filed individually and signed by an attorney-in-fact on Mr. Lister's behalf.